A 12-week safety extension study of oral ELND005 for treatment of agitation and aggression in patients with moderate to severe A - Bronson Healthcare

Alzheimer's Disease Safety Extension

A 12-week safety extension study of oral ELND005 for treatment of agitation and aggression in patients with moderate to severe Alzheimer's disease.

Objective

The purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease. Eligible patients will have a diagnosis of moderate to severe Alzheimer’s disease and have significant agitation and/or aggression which has not responded to other treatments.

ClinicalTrials.Gov Number
NCT01735630
Principal Investigator(s)
Nadeem Mirza, MD
Sponsor(s)
Elan Pharma International Limited
Contact
Gail Massey, RN, BS at 269-341-8774
or masseyg@bronsonhg.com
How to Participate
Subjects will be randomly assigned to either the investigational drug or placebo and will be followed for 12 weeks to evaluate the effectiveness and safety of the new drug. About 400 patients will enroll in the study at multiple sites.
More information can be found here.

Location

  • Bronson LakeView Neurobehavioral Health
    404 Hazen Street
    Suite L3
    Paw Paw, MI 49079
    Main: 269-657-1595
    Alternate: 800-656-3141
    Fax: 269-657-1534